Financial reports
10-K
2023 FY
Annual report
28 Mar 24
10-Q
2023 Q3
Quarterly report
13 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
10-Q
2023 Q1
Quarterly report
10 May 23
10-K
2022 FY
Annual report
3 Apr 23
NT 10-K
Notice of late annual filing
31 Mar 23
10-Q
2022 Q3
Quarterly report
7 Nov 22
10-Q
2022 Q2
Quarterly report
3 Aug 22
10-Q
2022 Q1
Quarterly report
6 May 22
10-K
2021 FY
Annual report
21 Mar 22
Current reports
8-K
Amendments to Articles of Incorporation or Bylaws
23 Apr 24
8-K
Sales Grew at an Average Rate of 14% Per Quarter During the Year
1 Apr 24
8-K
Entry into a Material Definitive Agreement
6 Mar 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
1 Mar 24
8-K
Submission of Matters to a Vote of Security Holders
16 Feb 24
8-K
Sunshine Biopharma, Inc. Announces Pricing of $10.0 Million Underwritten Public Offering
15 Feb 24
8-K
Entry into a Material Definitive Agreement
12 Feb 24
8-K
Departure of Directors or Certain Officers
30 Jan 24
8-K
Submission of Matters to a Vote of Security Holders
7 Dec 23
8-K
Revenues Up Significantly Over Last Year Due to a Key Acquisition
13 Nov 23
Registration and prospectus
424B4
Prospectus supplement with pricing info
14 Feb 24
S-1/A
IPO registration (amended)
9 Feb 24
S-1
IPO registration
1 Feb 24
S-8
Registration of securities for employees
8 Jan 24
424B3
Prospectus supplement
5 Jun 23
S-3
Shelf registration
25 May 23
D
$5.00 mm in equity / options, sold $5.00 mm, 1 investor
17 May 23
424B3
Prospectus supplement
20 May 22
S-3
Shelf registration
10 May 22
D
$19.5M in equity / options, sold $19.5M, 9 investors
29 Apr 22
Proxies
DEF 14C
Information statement
15 Mar 24
PRE 14C
Preliminary information
5 Mar 24
DEF 14C
Information statement
4 Mar 24
PRE 14C
Preliminary information
21 Feb 24
DEFA14A
Additional proxy soliciting materials
19 Oct 23
DEF 14A
Definitive proxy
18 Oct 23
DEF 14A
Definitive proxy
5 Sep 23
PRE 14A
Preliminary proxy
25 Aug 23
PRE 14A
Preliminary proxy
2 May 23
DEF 14C
Information statement
18 Jan 22
Other
EFFECT
Notice of effectiveness
13 Feb 24
CORRESP
Correspondence with SEC
9 Feb 24
CORRESP
Correspondence with SEC
9 Feb 24
UPLOAD
Letter from SEC
6 Feb 24
UPLOAD
Letter from SEC
29 Aug 23
CORRESP
Correspondence with SEC
8 Aug 23
UPLOAD
Letter from SEC
25 Jul 23
EFFECT
Notice of effectiveness
6 Jun 23
CORRESP
Correspondence with SEC
1 Jun 23
UPLOAD
Letter from SEC
1 Jun 23
Ownership
4
Steve N. Slilaty
5 Mar 24
SC 13G
L1 Capital Global Opportunities Master Fund, Ltd.
23 Feb 24
SC 13G
Altium Capital Management LP
21 Feb 24
SC 13G
ARMISTICE CAPITAL, LLC
14 Feb 24
4
Steve N. Slilaty
12 Feb 24
3
Marc Beaudoin
9 Feb 24
4
Camille Sebaaly
2 Dec 22
SC 13G
Chamoun Malek
2 Nov 22
3
Malek Chamoun
26 Oct 22
4
Camille Sebaaly
6 Jun 22